Vanilla, I only trade small percentages and never more than £5k. The has been movement out of some funds to grow my Avacta holding. Right now the market is not where it was.
Yes! What a result. Even better if he went to GDR full time to upset their board was not nice there today. Just wish they would stop trying to diminish our company name buy changing the v to a w just to annoy people.
Bet I get a response though ;-) Translucent filter....
Numptybuyer, I am not sure one would call me a posh ramper! But certainly a committed buyer trying to get to 750,000 shares, with not to far to go!
If the mm’s play nice this week and some drip feed buys we will be close.
I think this could be a very interesting week for everyone.
The key is to stay safe and don’t forget your social distancing!
Well, it is no secret to anyone on this board that I am very excited and positive about the future of Avacta and from any discussions on this board as well as the attention to detail from the Avacta management to present and deliver on goals in a timely and clear way, which for a Biotech company is no mean feat. The detailed expatiations found on the Avacta website as per my post below are so worthy of time.
The question that every investor wants to know is what does this mean to the companies market capitalisation and to investors the share price.
I think you will find some detailed guidance as an opinion from Myles (Aim Chaos), in his series of papers put together.
But if you would like a simple estimation of thoughts over the months ahead based on news, delivery of BAMS, POC, Stage 1 SARS-COV2 Neutraliser, Stage 1 AVA6000 clinical trials and beyond here goes. These are potential share price estimations and there are many factors which may affect these so please do not hold me to them!
1. Succesful BAMS clinical testing and first partnership with sales - Share price moving into the £2 to £3 range
2. Partnership to develop the SARS-COV2 Blocker - £2.50 to £3.50
3. Succesful approval for the Point of Care LFD with a minimum of two production partnerships and a number of large orders - £4 to £5
4. Increased sales of POC test and numbers growing exponentially around the world £5 to £8
5. Confirmation of first clinical trials for AVA6000 £5 to £8
6. Successful clinical trials for AVA6000 and moving to stage 2 and stage 3 clinical trials - £10 to £15
Beyond this and within 18 to 24 months with continued progress a share price in excess of £20.
I am sure many will make many comments on this and they are all welcome but this is my thoughts!
Have a good evening all!
Avacta is a Biotech company with two operating segments, the Therapeutics operations based at Avacta’s Cambridge site (pre|CISION™ ) and the Diagnostics operations ( Affimer® ) in Wetherby.
Avacta has two key areas - Affimer® technology a uniquely developed technology which is used as a diagnostic to find virus’s based on a human protein called Stefin A. The Affimer® platform is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families.
Affimer® technology projects with LG Chem just on licensing can be worth up to $310 million.
ADC project backed by Astra Zeneca for PBD Warheads - loaded affirmer drugs $500 million.
A joint venture in South Korea with Daewoong a leading Korean pharma company, to develop the next generation of cell and gene therapies, incorporating Affimer proteins to enhance the immune-modulatory effects. Avacta holds 45% of the business but the finance is provided by venture capitalists where the market potential is still too large to actually pinpoint as there are NDA's in place so the market information can't be shared. Huge potential!
The huge project with Affimer® technology with Moderna which again will give drug deliveries for mRNA delivery is still progressing. Huge potential!
Affimer® technology to detect Covid19 using Antigen tests the partners are Cytiva (LFD) and Adeptrix (BOMS) with distribution through 4 Mass Spectrometer suppliers (both close to production)
There are existing 5 other Affirmer evaluations progressing, 17 other projects already delivered for evaluation, and a further 7 development projects initiated!
Avacta’s pre|CISION™ technology can be utilised in a drug conjugate linker or to generate chemotherapy pro-drugs that are only activated in the tumour.
When added to a chemotoxin, the pre|CISION™ substrate prevents the chemotoxin from entering cells and therefore renders it inert until the substrate is cleaved in the tumour microenvironment. Using this pro-drug approach, the systemic exposure to the chemotoxin is dramatically reduced, and the safety and therapeutic window of these powerful anti-cancer treatments are improved.
pre|CISION™ partnerships which are looking to start with opportunities in AST, Breast and Ovarian cancer the EU/ US market potential is around $1.5 billion.
Research Opportunities for the reader:
Broker Note: https://mcusercontent.com/d9ebd7c1aa0f3dbc5fab42eca/files/28b0a706-057a-4dda-bc5f-e24c2afca3cd/AvactaGroupplc_24_6_20_FINAL_BG.01.pdf
The last Presentation:
https://youtu.be/DzoxXCB4or0 - from 1hr 33min 50 seconds
Latest from Avacta: https://avacta.com/how-diagnostic-test-performance-is-measured/
A good read from a well-known researcher is found here:
Investment decision for 2020? Surely it looks good!
Chiron, welcome to the board! You make some great points. The antibody tests always seem pointless to me as the key for safety is not having or carrying the virus. Public transportation and work places, and leisure venues are key places for rapid testing. The rapid tests will be key to success of control, but the key will be bringing the price low enough to make it affordable to everyone. Initially I am sure the costs of £10 plus for the test will be a starting point. But the real target price must surely be less than £2 per test based on high production numbers and volume must be the target, to ensure real mass testing , in the hundreds of millions. This will make the test unbeatable.
Looking at the test that the European governments are trying with the population over the weeks ahead, and given people soon become complacent we are very likely to see a rapid increase in numbers again and this will mean localised lockdowns.
As an investor here for reasons explained many times, but we should expect to see over the weeks ahead a massive increase in our market valuation. For those who think differently then they only have to look at the numbers in various countries in the world where the increase is almost out of control.
With BAMS, POC, pre|CISION SARS-COV2 blocker in development and then the pre|CISION chemotherapy program of therapeutics in the short term pipeline we are set for a pioneering opportunity not just for investors, but for those in most need and that underlines Avacta’s incredible position through exceptional research and drive as a business.
Let’s hope they succeed at every level.
Avacta, actually see the US as the key market. That is why the Boohoo distribution network for the POC LFD is via MEDUSA19.
The network via Pretty Little Thing in the US is massive.
The timing is going to be perfect. The UK market is much smaller.
Whilst we are desperate for Our mass testing to become available, the almost more important development is the collaborative work with the Centre for Virus Research at the University of Glasgow has shown that Affimer reagents which bind to the SARS-COV-2 virus spike protein prevent infection of human cells by a SARS-COV-2 model virus and therefore provide a potential therapy for COVID-19 infection.
Recently, Avacta reported that several of the Affimer reagents that had been generated to develop COVID-19 antigen tests inhibited the interaction between the coronavirus' spike protein and a receptor found on human cells, called ACE2, which the virus spike protein binds to as the first step in infecting cells.
Avacta has now successfully completed the initial phase of a collaboration with Professor David Bhella at the University of Glasgow showing that these "neutralising" Affimer reagents prevent a SARS-COV-2 model virus from entering human cells and therefore provide a potential therapy for COVID-19.
Affimer reagents have key benefits compared with antibodies as virus neutralising therapies: Their small size and high solubility means that a much higher concentration of Affimer molecules can be used in the drug formulation to more effectively block the spike proteins on each virus particle and better protect the patient; bispecific and trispecific Affimer neutralising therapies that bind to more than one part of the spike protein could ensure the effectiveness of the neutralising therapy even if the virus' spike protein mutates.
Neutralising therapies could be given to those exposed to the virus, such as health and social-care workers, to prevent infection, as well as to patients already infected by the virus, to help treat and prevent disease progression. There is ongoing significant investment by large pharmaceutical companies such as AstraZeneca, GSK, Boehringer Ingelheim and others to develop neutralising therapies for COVID-19.
Given the excellent performance of these novel reagents in the assays, and the other benefits of Affimer reagents, there should be considerable interest from potential partners in developing them as a therapy for COVID-19.
The next announcement from Avacta on this massive break through will be hugely valuable and this partnership when it is announced will be transformational for all their therapeutic Affimer technology.
Could this come this week? I hope it comes very soon. It will again take many months to go through the testing and stage 1 clinical trials, but this is the key to stopping the the danger in 2021.
Good morning Martin3042,
The point I think we need to be aware of is that there actually multiple LFD manufacturers around the world and for Avacta to get global coverage it will need to use many of them. As with many medical devices sold by the large pharmaceutical companies you will find that there are multiple 1st tier suppliers of devices who sub-contract manufacturer.
In this case Cytiva do the prototypes and create the finalised designs and this specification is passed to the 1st tier manufacturers to build the devices. This speeds up the process and reduces risk. The UK and the US will be two of those centres. But there will be many more if the quantities required are as high as we might expect.
I hope this helps remove your worries.
Mstar, I think you will still see huge publicity on all progress with other partnerships. In Alastair Smith’s company presentations he went through many of these in passing but news will come and the publicity from these projects will help Avacta’s global profile which will make news in the Lancet and other publications used in the world of medicine.
We will benefit too.
Keeping focus on the Pre|CISION Affimer technology, the strength of the attraction of the Affimer loaded with a high concentration of the chemotherapy conjugate directly to the cancer cells / tumour as tested in initial tests has shown that the mice that had the tumours all survived. This in humans would be a huge step forward.
I mentioned earlier the opportunity for diagnostic testing uses my Affimers to find specific cancer cells. This kind of revolution in detecting and killing the cells, without multiple scans, radiotherapy, multiple blood tests and the weeks it takes even with the highest priority patients would increase survival and quality of life.
The change in a very fit person after one session of chemotherapy is incredible, within 12 hours they go from almost super fit to so tired they need to sleep for 12 to 18 hours a day. Note not all chemotherapy has the same side effects. But the reduction on ability and the effect on people’s ability to cope. Let alone the massive risk of infection meaning many patents have multiple stays in specialist oncology wards during chemotherapy is so intense for patients and careers.
These are all such positive opportunities for the pre|CISION therapeutics.
Keep safe all and have a good evening.
Jonesrichard, a much higher market cap is coming over the months ahead, how it it gets and when is a question we cannot answer. The role of the worlds population in following instruction will decide if the virus spreads and how large the uptake will be for testing. It should be massive and our product should be key to global testing.
From my posts tonight you will be well aware where my priorities lie.
Last year my wife went through full treatment for oesophageal cancer and this resulted in her having her oesophagus removed. The follow up was additional chemotherapy and radiotherapy. The recovery is very slow and the long term side effects are very difficult. Living with nausea everyday. They make a new oesophagus from the tummy so your tummy size is reduced. She has very low energy, and her life is very restricted. She has had throat stretches, tummy stretches and she gets amazing care from the NHS and her support team. Early diagnosis and targeted treatment may have meant reduced surgery. But she had the big one, an 11 hour operation.
Trust me we both see the benefits in this treatment and if Avacta can succeed it will be huge step forward in chemotherapy and save many more lives.
Chemotherapy effects the immune system to a critically low level, takes away the sense of taste, hair loss as well as many other horrendous side effects. This is why so many give up the fight.
My passion of this company to succeed is way more than from a financial gain.
If I am positive and seen as a cheer leader for Avacta, I think people will have more understanding of my position and that of my good lady.
I am sorry for your loss and I wish you all the very best. Thanks for your kind words.
This is from the recent cash raise and this will accelerate Avacta’s potential:
- £10 million is ready for a rapid scale-up of Diagnostics Business,
- Working capital for the COVID-19 testing opportunity
- Expansion of in-house diagnostics product development capabilities including
facilities, capital equipment; scientific, commercial and senior leadership teams
- Acceleration of broader diagnostics product pipeline and commercial partnerships
-£38 million is ready to accelerate the Expansion of Pipeline of Differentiated Cancer Therapies:
- Rapidly growing the pre|CISION™ pre-clinical pipeline and delivering pre-clinical packages for several pro-drugs (pre|CISION™ velcade, paclitaxel and oxaliplatin).
- Expanding the Affimer® immunotherapy pipeline (PDL1-TGFß inhibitor and PDL1-cytokine bispecifics).
- IND/CTA filings for one or more Affimer immunotherapies (TMAC drug conjugate (PDL1-IDASH) or first bispecific candidate) and one or more pre|CISION pro-drugs.
- Obtain first-in-human data for the Affimer® platform.
- UK phase I clinical trial for first pre|CISION™ chemotherapy AVA6000 pro-doxorubicin covered by current cash reserves, with the proceeds of the Fundraise being used to fund IND filing AVA6000.
- Total Number of Shares is now 235,152,097
- Avacta has a new significant STRATEGIC US investor added to its shareholder base
- Employees are getting shares which will reward there hardwork
Alastair Smith and the Board "anticipates strong near-term news flow relating to the COVID-19 test developments with Cytiva and Adeptrix, as well as commercial and technical progress in the established therapeutic and diagnostics businesses, allowing the Company to concurrently achieve multiple value inflection points that we expect will deliver substantial shareholder returns. I look forward to updating the market on our continued progress."
I expect a very strong news flow and a new partnership which will really open up a very strong future for Avacta - Think pre|CISION™ Therapeutics!! Attaching drugs to Affimers and you have a precision drug warhead with reduced or no side effects! This is where the real value will come!
The targets for future Affimer pre|CISION
Avacta has so much potential in this particular area.
The first is AVA6000 Pro-doxorubicin, Doxorubicin has been a standard of care treatment for advanced soft tissue sarcoma (ASTS) for 40 years. Treatment is currently limited to six cycles due to cumulative cardio-toxicity. However, the global market for this generic drug is still $1bn. AVA6000 Market Opportunity for three opportunities ASTS, breast and ovarian cancer, with peak sales for a safer and more efficacious form of dox in the US/EU alone is estimated to be $1.5bn pa with a 5-10% royalty to Avacta plus development milestones in the near term. This is an incredible prospect!
But then the opportunities to use the recent funds to develop the additional pipeline of pre|CISION pro-drugs, some of which have already been synthesized, with an addressable market of many $billions per year.
Including these drugs but not limited to:
• preCISION Velcade
• preCISION Paclitaxel
• preCISION Oxaliplatin
• preCISION Gemcitabine
• preCISION Capecitabine
• preCISION PARP inhibitor
• preCISION PD-1 Inhibitor
• preCISION AKT inhibitor
• preCISION Balixafortide
The combination of Avacta’s two proprietary platforms to deliver chemotherapy and immunotherapy in a single drug molecule has two key points:
Released in the tumour by the preCISION linker chemistry.
• Selected to kill tumour cells and create an inflammatory event that recruits the immune system.
• Potential for a pipeline of TMACs using different immuno-active warheads
Then the Affimer Immunotherapy:
• Supports the immune attack on the tumour by blocking the signal the tumour uses to evade the immune system.
• Potential of a pipeline of immunotherapy and targeting Affimers including bispecifics
If the trials are successful with AVA6000 the developments in these other treatments will surely be accelerated. Within 2 to 3 years we could see the results of these developments being used in Oncology clinics around world saving lives.
This area has massive potential!
This presentation will help understand the pre|CISION chemotherapy treatment in the first trial coming later this year.
I hope this helps many trying to see where this is going.
When we look at the potential for Avacta it is all about Affimer technology.
This is a patented technology which is used to detect proteins and works like a magnet. The Affimer is a powerful magnet and the target is like particles of iron fillings and those targets are found quickly in the body.
We have seen that Avacta have developed the pre|CISION technology for delivering a drug to a target, with the focus on chemotherapy drugs to cancer cells.
Then our focus is currently on diagnostics and right now having a group of Affimers which can detect the protein on the spike on the Covid19 virus. This will come to market either in the form of lab diagnostic or on a test which will use a simple strip like a pregnancy test called a lateral flow device. This Avacta test will use saliva.
The potential is to be able to use Affirmers for diagnostics in many other deceases and illnesses. But given the work in cancer treatments which will go through stage 1 trials late this year and completed in Q1 2021, it is more than possible that Affirmers could be used for diagnostics in oncology. This would speed up the opportunity to treat a patient. The company have not given anything of this away at this point, but it must be a strong possibility. Imagine you have a simple diagnostic test to specific cancers and then you could use a targeted treatment to destroy the cancer cells, the whole oncology process could be simplified and this would save billions financially and of course save lives. The combination for Avacta IP could prove to be incredible.
It is a question I think I would like to see answered by Alastair Smith at some point in the future.
Does anyone else think this is possible? The impact would be huge.